Intravesical BCG instillations for the treatment of superficial bladder tumours in renal transplant recipients;Utilisation des instillations intra-vésicales de bacille de calmette et guérin (BCG) pour le traitement des tumeurs superficielles de vessie chez les patients transplantés rénaux

Progres en Urologie

Volumn 16, Issue 1, 2006, Pages 32-35

  Neuzillet, Yann ^a   Davin, Jean Louis ^b   Lechevallier, Eric ^a  

^a Child and Adolescent Psychopathology Unit Salvator Hospital Public Assistance Marseille Hospitals University Aix Marseille II   (France)

^b INSTITUT SAINTE CATHERINE   (France)

Author keywords

BCG; Bladder; Cancer; Renal transplantation; Treatment

Indexed keywords

BCG VACCINE; IMMUNOLOGICAL ADJUVANT;

BLADDER TUMOR; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; BCG VACCINE; HUMANS; KIDNEY TRANSPLANTATION; URINARY BLADDER NEOPLASMS;

EID: 33744550128     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. AL KHALIFA M., ELFVING P., MANSSON W., COLLEEN S., HELLSTEN S., DUCHEK M., NYBERG G., CALLAGHAN P., RADEMARK C., ERIKSSON R., OLSSON R., HAGBERG G., NELSON C.E. : The effect of isoniazid on BCG-induced toxicity in patients with superficial bladder cancer. Eur. Urol., 2000 ; 37 : 26-30.
2. ALEXANDROFF A.B., JACKSON A.M., O'DONNELL M.A., JAMES K.: BCG immunotherapy of bladder cancer : 20 years on. Lancet, 1999 ; 353 : 1689-1694.
3. ALEXANDROFF A.B., ROBINS R.A., MURRAY A., JAMES K. : Tumour immunology : false hopes-new horizons ? Immunol Today 1998 ; 19 : 247-250.
4. BECICH M.J., CARROL S., RATLIFF T.L. : Internalisation of bacillus Calmette-guerin by bladder tumor cells. J. Urol., 1991 ; 145 : 1316-1324.
5. BIRKELAND S.A., STORM H.H., LAMM L.U., BARLOW L., BLOHME I., FORSBERG B., EKLUND B., FJELDBORG O., FRIEDBERG M., FRODIN L. : Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer. 1995 ;60: 183-9.
6. BOHLE A., BRANDAU S. : Immune mechanisme in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J. Urol., 2003 ; 170 : 964-969.
7. BÖLHE A, BOCK P.R. : Intravesical bacillus Calmete-Guerin versus mitomycin C in superficial bladder cancer : formal meta-analysis of comparative studies on tumor progression. Urology, 2004 ; 63 : 682-687.
8. BÖLHE A., JOCHAM D., BOCK P.R. : Intravesical bacillus Calmete-Guerin versus mitomycin C in superficial bladder cancer : formal meta-analysis of comparative studies on recurrence and toxicity. J. Urol., 2003 ; 169 : 90-95.
9. BUZZEO B.D., HEISEY D.M., MESSING E.M. : Bladder cancer in renal transplant recipients. Urology, 1997 ; 50 : 525-528.
10. DAVID K.M., MORRIS J.A., STEFFEN B.J., CHI-BURRIS K.S., GOTZ V.P., GORDON R.D. : Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes. Clin. Transplant., 2005 ; 19 : 279-285.
11. DE BOER E.C., DE JONG W.H., STEERENBERG P.A., AARDEN L.A., TETTEROO E., DE GROOT E.R., VAN DER MEIJDEN A.P., VEGT P.D., DEBRUYNE F.M., RUITENBERG E.J. : Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer. Cancer Immunol. Immunother., 1992 ; 34 : 306-312.
12. DE BOER E.C., STEERENBERG P.A., VAN DER MEIJDEN A.P., VAN KLINGEREN B., DE JONG W.H., DEBRUYNE F.M., RUITENBERG E.J.: Impaired immune response by isoniazid treatment during intravesical BCG administration in the guinea pig. Prog. Clin. Biol. Res., 1992 ; 378 : 81-93.
13. DERESIEWICZ R.L., STONE R.M., ASTER J.C. : Fatal disseminated mycobacterial infection following intravesical bacillus Calmette-Guerin. J. Urol., 1990 ; 144 : 1331-1334.
14. DUREK C., RUSCH-GERDES S., JOCHAM D., BOHLE A. : Interference of modern antibacterials with bacillus Calmette-Guerin viability. J. Urol. 1999 ; 162 : 1959-1962.
15. GAYA S.B., REES A.J., LECHLER R.I., WILLIAMS G., MASON P.D. : Malignant disease in patients with long-term renal transplants. Transplantation, 1995 ; 59 : 1705-1709.
16. GUBA M., VON BREITENBUCH P., STEINBAUER M., KOEHL G., FLEGEL S., HORNUNG M., BRUNS C.J., ZUELKE C., FARKAS S., ANTHUBER M., JAUCH K.W., GEISSLER E.K. : Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis : involvement of vascular endothelial growth factor. Nat. Med., 2002 ; 8 : 128-135.
17. Halloran P.F. : Immunosuppressive drugs for kidney transplantation. N. Engl. J. Med., 2004 ; 351 : 2715-2729.
18. IRANI J., BERNARDINI S., BONNAL J.L., COLOBY P., COLOMBEL M., DAVIN J.L., LAURENT G., LEBRET T., MAIDENBERG M., MAZEROLLES C., PARIENTE J.L., PFISTER C., ROY C., SAINT F., THEODORE C., COMITE DE CANCEROLOGIE DE L'ASSOCIATION FRANCAISE D'UROLOGIE. Recommandation 2004 : Tumeurs Urotheliales. Prog. Urol., 2004 ; 14 : 959-996.
19. JACKSON A.M., JAMES K. : Understanding the most successful immunotherapy for cancer. The Immunologist, 1994 ; 2 : 208-215.
20. JANEWAY C.A., TRAVERS P., WALPORT M., SHLOMCHIK M. : Immunobiology. 5th ed. New York and London, Garland Publishing, 2001, part V.
21. KAEMPFER R., GEREZ L., FARBSTEIN H., MADAR L., HIRSCHMAN O., NUSSINOVITCH R., SHAPIRO A. : Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J. Clin. Oncol., 1996 ; 14 : 1778-1786.
22. KURODA K., BROWN E.J., TELLE W.B., RUSSELL D.G., RATLIFF T.L.: Characterization of the internalisation of bacillus Calmette-Guerein by human bladder tumour cell. J. Clin. Invest., 1993 ; 91 : 69-76.
23. KYLLONEN L., PUKKALA E., EKLUND B. : Cancer incidence in a kidney-transplanted population. Transpl. Int., 1994 ; 7 : 350-352.
24. LOTTE A., WASZ-HOCKERT O., POISSON N., DUMITRESCU N., VERRON M., COUVET E. : BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics. Adv. Tuberc. Res., 1984 ; 21 : 107-193.
25. MARCEN R., PASCUAL J., TATO A.M., TERUEL J.L., VILLAFRUELA J.J., FERNANDEZ M., TENORIO M., BURGOS F.J., ORTUNO J. : Influence of immunosuppression on the prevalence of cancer after kidney transplantation. Transplant. Proc., 2003 ; 35 : 1714-1716.
26. MASTER V.A., MENG M.V., GROSSFELD G.D., KOPPIE T.M., HIROSE R., CARROLL P.R. : Treatment and outcome of invasive bladder cancer in patients after renal transplantation. J. Urol., 2004 ; 171 : 1085-1088.
27. MCAVENEY K.M., GOMELLA L.G., LATTIME E.C. : Induction of TH1-and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumour MB-49 and BCG immunotherapy. Cancer Immunol. Immunother., 1994 ; 39 : 401-406.
28. MEIER-KRIESCHE H.U., MORRIS J.A., CHU A.H., STEFFEN B.J., GOTZ V.P., GORDON R.D., KAPLAN B. : Mycophenolate mofetil vs azathioprine in a large population of elderly renal transplant patients. Nephrol. Dial. Transplant., 2004 ; 19 : 2864-2869.
29. MEIER-KRIESCHE H.U., STEFFEN B.J., HOCHBERG A.M., GORDON R.D., LIEBMAN M.N., MORRIS J.A., KAPLAN B. : Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am. J. Transplant., 2003 ; 3 : 68-73.
30. PALOU J., ANGERRI O., SEGARRA J., CAPARROS J., GUIRADO L., DIAZ J.M., SALVADOR-BAYARRI J., VILLAVICENCIO-MAVRICH H. : Intravesical bacillus Calmette-Guerin for the treatment of superficial bladder cancer in renal transplant patients. Transplantation. 2003 ; 76 : 1514-1516
31. PENN I. : Occurrence of cancers in immunosuppressed organ transplant recipients. Clin. Transpl., 1998 ; 147-158.
32. PRESCOTT S., JAMES K., HARGREAVE T.B., CHISHOLM G.D., SMYTH J.F. : Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J. Urol., 1992 ; 147 : 1636-1642.
33. RATLIFF T.L., RICHTEY J.K., YUAN J.J., ANDRIOLE G.L., CATALONA W.J. : T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J. Urol. 1993.; 150 : 1018-1023.
34. RISCHMANN P., BITTARD H., CHOPIN D., COLOBY P., DAVIN J.L., IRANI J., LEBRET T., LEFRERE M.A., MAIDENBERG M., MARECHAL J.M., PARIENTE J.L., THEODORE C. : Comité de cancérologie de l'Association Française d'Urologie. Recommandation 2002 : Tumeurs Urotheliales. Prog. Urol., 2002 ; 12 : 15-27.
35. RISCHMANN P., DESGRANDCHAMPS F., MALAVAUD B., CHOPIN D.K. : BCG intravesical instillations : recommendations for side-effects management. Eur. Urol., 2000 ; 37 : 33-36.
36. SAINT F., IRANI J., PATARD J.J., SALOMON L., HOZNEK A., ZAMMATTIO S., DEBOIS H., ABBOU C.C., CHOPIN D.K. : Tolerability of bacille Calmette-Guerin maintenance therapy for superficial bladder cancer. Urology, 2001 ; 57 : 883-888.
37. SCHNITZLER M.A., CRAIG K.E., HARDINGER K.E., LOWELL J.A., BRENNAN D.C. : Mycophenolate mofetil is associated with less death with function than azathioprine in cadaveric renal transplantation. Nephrol. Dial. Transplant., 2003; 18 : 1197-200.
38. STARZL T.E., NALESNIK M.A., PORTER K.A., HO M., IWATSUKI S., GRIFFITH B.P., ROSENTHAL J.T., HAKALA T.R., SHAW B.W. JR, HARDESTY R.L. : Reversibility of lymphoma and lymphoproliférative lesions developing under cyclosporin-steroid therapy. Lancet 1984 ; 1 : 583-587.
39. THANHAUSER A., BOHLE A., SCHNEIDER B., ET AL. : The induction of bacillus-Calmette-Guerin-activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol. Immunother., 1995 ; 40 : 103-108.
40. VEGT P.D., VAN DER MEIJDEN A.P., SYLVESTER R., BRAUSI M., HOLTL W., DE BALINCOURT C. : Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer ? Interim results of European Organization for Research and Treatment of Cancer Protocol., 30911. J. Urol., 1997 ; 157 : 1246-1249.
41. WANG H.B., HSIEH H.H., CHEN Y.T., CHIANG C.Y., CHENG Y.T. : The outcome of post-transplant transitional cell carcinoma in 10 renal transplant recipients. Clin. Transplant., 2002 ; 16 : 410-413.